|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
The area most frequently deleted resided on 16q23.1, 3.5 MB downstream of the area most significantly associated with survival, and included the tumor suppressor gene ADAMTS18 and the cell recognition gene CNTNAP4.
|
18398821 |
2008 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.
|
17546048 |
2007 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We previously found ADAMTS18 as frequently methylated tumor suppressor gene (TSG) for multiple carcinomas, however, its biological functions and underlying molecular mechanisms in breast carcinogenesis remain unknown.
|
28503860 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that Adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated Wnt/β-catenin and p38MAPK/ERK1/2 signaling and promotes colon cancer in this mouse model.
|
28145888 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We conclude that ADAMTS18 gene hypermethylation may be involved in the tumorigenesis of ccRCC and may serve as a novel biomarker for this disease.
|
25569086 |
2015 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In summary, epigenetic regulation of ADAMTS18 was associated with carcinogenesis.
|
19806480 |
2010 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Tissue levels of ADAMTS18 in patients with primary cancer were significantly lower compared with those with metastasis.
|
28362704 |
2018 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Nude mouse model further confirmed that ADAMTS18 suppressed breast cancer metastasis in vivo.
|
28503860 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Melanoma cells expressing mutant ADAMTS18 had reduced cell migration after short hairpin RNA-mediated knockdown of ADAMTS18, suggesting that ADAMTS18 mutations promote growth, migration, and metastasis in melanoma.
|
21047771 |
2010 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Tissue levels of ADAMTS18 in patients with primary cancer were significantly lower compared with those with metastasis.
|
28362704 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
ADAMTS18 is a member of a secreted Zn-metalloproteinase ADAMTS family, and has been implicated in development, hemostasis, and various malignancies.
|
28843853 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
ADAMTS18 dysregulation plays an important role in many disease processes including cancer.
|
28503860 |
2017 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
We previously found ADAMTS18 as frequently methylated tumor suppressor gene (TSG) for multiple carcinomas, however, its biological functions and underlying molecular mechanisms in breast carcinogenesis remain unknown.
|
28503860 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
ADAMTS18 dysregulation plays an important role in many disease processes including cancer.
|
28503860 |
2017 |
|
Knobloch syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Identification of ADAMTS18 as a gene mutated in Knobloch syndrome.
|
21862674 |
2011 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Thus, through functional epigenetics, we identified ADAMTS18 as a novel functional tumor suppressor, being frequently inactivated epigenetically in multiple carcinomas.
|
17546048 |
2007 |
|
Knobloch syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We named the second unmapped locus for Knobloch syndrome KNO2.
|
14695535 |
2004 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Compared with normal lung tissue, ADAMTS18 in lung tumors was frequently methylated.
|
30417422 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study suggests that ADAMTS18 promoter methylation is a potential epigenetic biomarker for early detection of lung cancer and warrants investigation as a therapeutic target for early-stage lung cancer.
|
30417422 |
2019 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study suggests that ADAMTS18 promoter methylation is a potential epigenetic biomarker for early detection of lung cancer and warrants investigation as a therapeutic target for early-stage lung cancer.
|
30417422 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study suggests that ADAMTS18 promoter methylation is a potential epigenetic biomarker for early detection of lung cancer and warrants investigation as a therapeutic target for early-stage lung cancer.
|
30417422 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADAMTS18 deficiency promotes atherosclerosis in apolipoprotein E-deficient mice.
|
29169989 |
2018 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADAMTS18 deficiency promotes atherosclerosis in apolipoprotein E-deficient mice.
|
29169989 |
2018 |
|
Carotid Artery Thrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADAMTS18 deficiency accelerated FeCl<sub>3</sub>-induced carotid artery thrombosis and aggravated postischemic cerebral infarction in mice.
|
29421655 |
2018 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
ADAMTS18 deficiency accelerated FeCl<sub>3</sub>-induced carotid artery thrombosis and aggravated postischemic cerebral infarction in mice.
|
29421655 |
2018 |